Eli Lilly’s Cyramza meets primary endpoint in phase 3 liver cancer trial
The company has revealed the top-line results from the phase 3 study of Cyramza as a single agent in the second-line treatment of people with hepatocellular carcinoma (HCC).
The US Food and Drug Administration (FDA) has granted clearance for RiboX Therapeutics’ investigational new drug (IND) application to commence a Phase I/IIa clinical trial of RXRG001, circular RNA therapy.
Advanced CCSC is the deadliest non-melanoma skin cancer. Cemiplimab is an investigational human monoclonal antibody targeting the checkpoint inhibitor PD-1 (programmed cell death protein-1). The MAA for cemiplimab
The FDA has accepted AstraZeneca and MedImmune’s biologics license application (BLA) for moxetumomab pasudotox, which is an investigational anti-CD22 recombinant immunotoxin and potential new medicine to treat adult